Categories: BioTechDevelopmentDrug
Most drug development is focused on targeting cells, overlooking the extracellular matrix that surrounds the cells. Presence of excessive matrix proteins are linked to therapeutic resistance and poor patient outcomes in fibrotic tumors and organ fibrosis. The matrix offers druggable biological real-estate to targets nodes that drive disease progression. At Tandem Therapeutics our goal is to precision target this barrier and bring drugs to this disease extracellular matrix thereby enhancing safety and efficacy. Using evolutionarily optimised peptides, we are decoding complex matrix-disease biology to create breakthrough solutions for patients burdened with fibrotic diseases.
Investors 2
Mentions in press and media 4
| Date | Title | Description |
| 20.06.2024 | Sustainable start-ups excel at the W.A de Vigier Award |
From over 200 submitted projects, the jury picked their Top 15 in February. The 15 CEOs went through an interview process and presented their ideas to the Foundation Board, who chose the final ten nominees. At the award ceremony on June 19... |
| 19.04.2024 | Wyss Zurich expands portfolio |
Wyss Zurich is a joint accelerator of the University of Zurich and ETH Zurich, funded by a generous donation from the Swiss entrepreneur and philanthropist Dr Hansjörg Wyss. By providing projects with capital and access to infrastructure a... |
| 04.04.2024 | The top 15 startups in de Vigier Award revealed |
More than 200 candidates applied for the 2024 W.A de Vigier Award, one of the most important competitions in the Swiss startup ecosystem, and only 50 made it to the shortlist. During the selection Day on February 28, the jury nominated the... |
| 19.04.2023 | Ten biotech startups head to Boston | |
Reviews 0
